<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02894723</url>
  </required_header>
  <id_info>
    <org_study_id>0216-15-COM2</org_study_id>
    <nct_id>NCT02894723</nct_id>
  </id_info>
  <brief_title>L-arginine Treatment in Mild Hypertension</brief_title>
  <acronym>LAHN</acronym>
  <official_title>Efficacy of L-arginine Treatment on Blood Pressure Control Patients With Stage 1 Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meir Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meir Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Essential Hypertension is characterized by endothelial dysfunction due to reduced nitric&#xD;
      oxide (NO) bioavailability. Impairment in nitric oxide-mediated vasodilatation in human&#xD;
      brachial, coronary, and renal arteries has been demonstrated in patients with essential&#xD;
      hypertension. Administration of L-arginine, a NO substrate yeld controversial results.&#xD;
&#xD;
      The purpose of the present study, double blind and matched for age, sex and body mass index&#xD;
      (BMI), is to assess the efficacy of L-arginine treatment on blood pressure (BP) control and&#xD;
      arterial stiffness in patients with stage1 hypertension.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Scientific background&#xD;
&#xD;
      Essential Hypertension is characterized by endothelial dysfunction with impaired&#xD;
      vasorelaxation.&#xD;
&#xD;
      Reduced nitric oxide bioavailability, which is considered a hallmark of endothelial&#xD;
      dysfunction, plays an important role in mediating blood pressure elevation. Accumulating&#xD;
      evidence demonstrates a critical role of nitric oxide in blood pressure regulation. Released&#xD;
      from the endothelial cells, nitric oxide increases 30,50-cyclic-guanosine monophosphate&#xD;
      (cGMP) production and subsequent cGMP-dependent protein kinase (PKG) activation in the&#xD;
      underneath vascular smooth muscle cells (VSMCs), resulting in vasodilatation. The&#xD;
      investigators and others have shown that inhibition of NO synthesis increase blood pressure&#xD;
      in normal pregnant rats and different animal models. In vivo studies confirmed an essential&#xD;
      role of nitric oxide in vasorelaxation of large human arteries. Impairment in nitric&#xD;
      oxide-mediated vasodilatation in brachial, coronary, and renal arteries has been demonstrated&#xD;
      in patients with essential hypertension.&#xD;
&#xD;
      Several mechanisms have been found responsible for nitric oxide deficiency in hypertension.&#xD;
      One of them is deficit of the NO substrate, L-arginine. L-arginine transport is impaired in&#xD;
      hypertensive and normotensive patients with a genetic background of essential hypertension,&#xD;
      and the offspring of essential hypertensive patients are characterized by a reduced response&#xD;
      to acetylcholine linked to a defect in the nitric oxide pathway. These data represent the&#xD;
      link between L-arginine and the onset of essential hypertension. The Km of endothelial nitric&#xD;
      oxide synthase for L-arginine is about 3mmol/l, but the concentration of plasma L-arginine&#xD;
      rarely falls below 60mmol/l in pathological conditions. An elevation in asymmetric&#xD;
      dimethylarginine (ADMA, an endogenous NO competitive inhibitor) levels may explain this&#xD;
      'L-arginine paradox'. The administration of excess exogenous L-arginine displaces the&#xD;
      competitive inhibitor, improves intracellular transport of this amino acid, and restores NO&#xD;
      production to physiological levels. In fact L-arginine supplementation improved endothelial&#xD;
      dysfunction in hypertension.&#xD;
&#xD;
      Administration of L arginine in humans have not shown uniform blood pressure responses. A&#xD;
      meta-analysis published in 2011 was able to find only 11 articles dealing with l-arginine&#xD;
      administration and blood pressure. The population studies were heterogeneous. Compared with&#xD;
      placebo, oral L-arginine intervention was associated with an average net change ranging from&#xD;
      -23.0 to 2.8 mm Hg for SBP and from -11.0 to 1.0 mm Hg for diastolic BP. Most trials showed&#xD;
      an intervention-related trend toward BP reductions, but only a few reached statistical&#xD;
      significance.&#xD;
&#xD;
      Endothelial dysfunction leads to an increase in arterial stiffness, a known marker that&#xD;
      increases cardiovascular morbidity and mortality. Arterial stiffness can be measured by non&#xD;
      invasive methodology, e.g.; measuring carotid-femoral pulse wave velocity, augmentation&#xD;
      index, aortic pulse pressure and aortic systolic blood pressure.&#xD;
&#xD;
      Whether administration of l-arginine improved arterial stiffness in patients with mild&#xD;
      hypertension it is not known.&#xD;
&#xD;
      Arginoline is a dietary supplement that contains L-arginine at a concentration of 5 g/L. It&#xD;
      is possible to dilute with water or take chilled. It is produced by Pharmayeda, an Israeli&#xD;
      industry.&#xD;
&#xD;
      Clinical observational studies [personal communication] have shown that at a dose of 60&#xD;
      ml\day [10 gr of l-arginine] flow mediated vasodilation improves, suggesting an increase in&#xD;
      nitric oxide function.&#xD;
&#xD;
      Methods&#xD;
&#xD;
      Office Blood Pressure (OBP) measurement:&#xD;
&#xD;
      OBP will be measured with a Suntech 247 digital automated device. BP will be determined 3&#xD;
      times at one min. interval each. The mean of the second and third measurements will be noted&#xD;
      as the OBP of the visit.&#xD;
&#xD;
      ABPM:&#xD;
&#xD;
      24 hours ABPM will be performed with an Oscar 2 ABPM device of SunTech Medical. The Oscar 2&#xD;
      ABPM device is clinically validated to all 3 internationally recognized protocols (British&#xD;
      Heart Society, American Society of Hypertension and the Association for the Advancement of&#xD;
      Medical Instrumentation).&#xD;
&#xD;
      Blood pressure is measured in a 20 min. interval at day time and a 30 min. interval at night&#xD;
      time. The patients are requested to fill a diary with their activities during the ABPM study,&#xD;
      including their subjective evaluation of the sleeping quality.&#xD;
&#xD;
      Measurement of arterial stiffness:&#xD;
&#xD;
      The SphygmoCor X-CEL System (AtCor Medical, Sydney, Australia) will be used.&#xD;
&#xD;
      The system derives (non invasively) the ascending aortic pressure waveform from the brachial&#xD;
      waveform using a validated generalised transfer function.&#xD;
&#xD;
      The SphygmoCor X-CEL system measures the carotid-femoral pulse wave velocity (PWV), the speed&#xD;
      of the arterial pressure waveform as it travels through the descending aorta to the femoral&#xD;
      artery, which is detected from simultaneously measured carotid and femoral arterial pulses.&#xD;
&#xD;
      Design&#xD;
&#xD;
      The study is a matched double blind study with an experimental group and a placebo group. As&#xD;
      the number of the groups is small (20 in each group) the patients will be matched according&#xD;
      to age, sex and BMI during the recruitment phase, in order to get to comparable groups. The&#xD;
      principal investigator is responsible of the matching.&#xD;
&#xD;
      The experimental group will receive arginoline 30 ml twice a day and the placebo group will&#xD;
      receive placebo at the same schedule&#xD;
&#xD;
      Visits:&#xD;
&#xD;
      Week -2:&#xD;
&#xD;
      Sign of informed consent&#xD;
&#xD;
      Office BP. Physical examination. BMI.&#xD;
&#xD;
      Blood exams: Hemoglobin (g%), urea (mg%), creatinine (mg%), Natrium (mEq/l), Potassium&#xD;
      (mEq/l), alanine transaminase (ALT),Aspartate aminotransferase (AST), gamma-glutamyl&#xD;
      transpeptidase (GGT), glucose, cholesterol and triglycerides. and lipid profile.&#xD;
&#xD;
      Urine analysis: microalbuminuria (morning spot)&#xD;
&#xD;
      All patients will receive a booklet with detailed information about healthy life style&#xD;
      recommendation to lower blood pressure.&#xD;
&#xD;
      Hypertensive patients on monotherapy will stop treatment.&#xD;
&#xD;
      Week 0&#xD;
&#xD;
      ABPM&#xD;
&#xD;
      Measurement of Central aortic blood pressure and arterial stiffness&#xD;
&#xD;
      Blind group allocation (experimental or placebo group).&#xD;
&#xD;
      Week 2&#xD;
&#xD;
      Office BP measurement.&#xD;
&#xD;
      Week 4&#xD;
&#xD;
      Office BP measurement&#xD;
&#xD;
      Week 6&#xD;
&#xD;
      Office BP measurement&#xD;
&#xD;
      Week 8: ABPM, office BP,&#xD;
&#xD;
      Repeat blood and urine exams as detailed at week -2.&#xD;
&#xD;
      Measurement of Central aortic blood pressure and Arterial stiffness&#xD;
&#xD;
      Statistical evaluation&#xD;
&#xD;
      Will be done using the IBM SPSS statistical software. Pi&lt;0.05 is considered significative&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood Pressure, mmHg</measure>
    <time_frame>baseline [visit 0] to eight weeks</time_frame>
    <description>change in systolic and/or diastolic blood pressure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Central aortic BP, mmHg</measure>
    <time_frame>baseline (visit 0) to eight weeks</time_frame>
    <description>changes in Central aortic BP values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse pressure (mmHg)</measure>
    <time_frame>baseline (visit 0] to eight weeks</time_frame>
    <description>changes in central pulse pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Augmentation Index (%)</measure>
    <time_frame>baseline (visit 0] to eight weeks</time_frame>
    <description>changes in augmentation index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>carotid femoral pulse wave velocity (m/s)</measure>
    <time_frame>baseline (visit 0] to eight weeks</time_frame>
    <description>changes in carotid femoral pulse wave velocity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>l-arginine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive L-arginine 30 ml twice a day for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>syrup</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive placebo, 30 ml twice a day for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>L-arginine</intervention_name>
    <description>30 ml arginoline contains 5 gr l-arginine</description>
    <arm_group_label>l-arginine</arm_group_label>
    <other_name>Arginoline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>syrup</intervention_name>
    <description>The same bottle of the experimental group, but without l-arginine</description>
    <arm_group_label>syrup</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Stage 1 hypertensive patients, with an office Systolic BP between 140-159 mmHg and/or&#xD;
             a diastolic BP between 9-99 mmHg , untreated or treated with monotherapy.&#xD;
&#xD;
          -  None to two risk factors [smoking, hyperlipidemia, obesity , family history of&#xD;
             cardiovascular disease].&#xD;
&#xD;
          -  BMI between 25 to 32.&#xD;
&#xD;
          -  Twenty for hours ambulatory blood pressure monitor (ABPM) with a mean Systolic BP of&#xD;
             130-149 mmHg and/or a mean Diastolic BP of 80-89 mmHg.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Use of any drug that may affect nitric oxide synthesis and/or blood pressure values&#xD;
             (nitrates, antihypertensive drugs, non steroidal anti-inflammatory drugs , steroids,&#xD;
             pseudoephedrine).&#xD;
&#xD;
          -  Diabetes mellitus.&#xD;
&#xD;
          -  Renal failure defined as estimated glomerular filtration rate (eGFR) less than 60&#xD;
             ml/min, using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.&#xD;
&#xD;
          -  A previous diagnosis of ischemic heart disease, Transient ischemic attack (TIA),&#xD;
             Stroke or peripheral arterial disease.&#xD;
&#xD;
          -  Patients with recurrent herpes and women who are planning pregnancy during the next&#xD;
             year.&#xD;
&#xD;
          -  Cancer treated with radiotherapy or chemotherapy during the last year.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eduardo Podjarny, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clalit Health Services</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eduardo Podjarny, MD</last_name>
    <phone>0528339193</phone>
    <email>epodjarny@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Naomi Nacasch, MD</last_name>
    <phone>0523815010</phone>
    <email>naomi.nacasch@clalit.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ADAM Institute of High Blood Pressure, Clalit Health Services</name>
      <address>
        <city>Herzliya</city>
        <state>Hasharon Area</state>
        <country>Israel</country>
      </address>
    </facility>
    <contact>
      <last_name>Eduardo Podjarny, MD</last_name>
      <phone>0523554815</phone>
      <email>epodjarny@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Tanaka Y, Tang G, Takizawa K, Otsuka K, Eghbali M, Song M, Nishimaru K, Shigenobu K, Koike K, Stefani E, Toro L. Kv channels contribute to nitric oxide- and atrial natriuretic peptide-induced relaxation of a rat conduit artery. J Pharmacol Exp Ther. 2006 Apr;317(1):341-54. Epub 2006 Jan 4.</citation>
    <PMID>16394199</PMID>
  </reference>
  <reference>
    <citation>Li Q, Youn JY, Cai H. Mechanisms and consequences of endothelial nitric oxide synthase dysfunction in hypertension. J Hypertens. 2015 Jun;33(6):1128-36. doi: 10.1097/HJH.0000000000000587. Review.</citation>
    <PMID>25882860</PMID>
  </reference>
  <reference>
    <citation>Joannides R, Haefeli WE, Linder L, Richard V, Bakkali EH, Thuillez C, Lüscher TF. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation. 1995 Mar 1;91(5):1314-9.</citation>
    <PMID>7867167</PMID>
  </reference>
  <reference>
    <citation>Panza JA, García CE, Kilcoyne CM, Quyyumi AA, Cannon RO 3rd. Impaired endothelium-dependent vasodilation in patients with essential hypertension. Evidence that nitric oxide abnormality is not localized to a single signal transduction pathway. Circulation. 1995 Mar 15;91(6):1732-8.</citation>
    <PMID>7882481</PMID>
  </reference>
  <reference>
    <citation>Treasure CB, Klein JL, Vita JA, Manoukian SV, Renwick GH, Selwyn AP, Ganz P, Alexander RW. Hypertension and left ventricular hypertrophy are associated with impaired endothelium-mediated relaxation in human coronary resistance vessels. Circulation. 1993 Jan;87(1):86-93.</citation>
    <PMID>8419028</PMID>
  </reference>
  <reference>
    <citation>Higashi Y, Oshima T, Ozono R, Watanabe M, Matsuura H, Kajiyama G. Effects of L-arginine infusion on renal hemodynamics in patients with mild essential hypertension. Hypertension. 1995 Apr;25(4 Pt 2):898-902.</citation>
    <PMID>7721451</PMID>
  </reference>
  <reference>
    <citation>Taddei S, Virdis A, Mattei P, Ghiadoni L, Sudano I, Salvetti A. Defective L-arginine-nitric oxide pathway in offspring of essential hypertensive patients. Circulation. 1996 Sep 15;94(6):1298-303.</citation>
    <PMID>8822983</PMID>
  </reference>
  <reference>
    <citation>Schlaich MP, Parnell MM, Ahlers BA, Finch S, Marshall T, Zhang WZ, Kaye DM. Impaired L-arginine transport and endothelial function in hypertensive and genetically predisposed normotensive subjects. Circulation. 2004 Dec 14;110(24):3680-6. Epub 2004 Nov 29.</citation>
    <PMID>15569830</PMID>
  </reference>
  <reference>
    <citation>Förstermann U, Sessa WC. Nitric oxide synthases: regulation and function. Eur Heart J. 2012 Apr;33(7):829-37, 837a-837d. doi: 10.1093/eurheartj/ehr304. Epub 2011 Sep 1. Review.</citation>
    <PMID>21890489</PMID>
  </reference>
  <reference>
    <citation>Böger RH. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the &quot;L-arginine paradox&quot; and acts as a novel cardiovascular risk factor. J Nutr. 2004 Oct;134(10 Suppl):2842S-2847S; discussion 2853S. doi: 10.1093/jn/134.10.2842S. Review.</citation>
    <PMID>15465797</PMID>
  </reference>
  <reference>
    <citation>Naseem KM. The role of nitric oxide in cardiovascular diseases. Mol Aspects Med. 2005 Feb-Apr;26(1-2):33-65. Epub 2005 Jan 24. Review.</citation>
    <PMID>15722114</PMID>
  </reference>
  <reference>
    <citation>Hishikawa K, Nakaki T, Suzuki H, Kato R, Saruta T. Role of L-arginine-nitric oxide pathway in hypertension. J Hypertens. 1993 Jun;11(6):639-45.</citation>
    <PMID>8397243</PMID>
  </reference>
  <reference>
    <citation>Ast J, Cieślewicz AR, Korzeniowska K, Bogdański P, Kazmierczak E, Olszewski J, Skołuda A, Jabłecka A. Supplementation with L-arginine does not influence arterial blood pressure in healthy people: a randomized, double blind, trial. Eur Rev Med Pharmacol Sci. 2011 Dec;15(12):1375-84.</citation>
    <PMID>22288298</PMID>
  </reference>
  <reference>
    <citation>Ast J, Jablecka A, Bogdanski P, Smolarek I, Krauss H, Chmara E. Evaluation of the antihypertensive effect of L-arginine supplementation in patients with mild hypertension assessed with ambulatory blood pressure monitoring. Med Sci Monit. 2010 May;16(5):CR266-71.</citation>
    <PMID>20424555</PMID>
  </reference>
  <reference>
    <citation>Gui S, Jia J, Niu X, Bai Y, Zou H, Deng J, Zhou R. Arginine supplementation for improving maternal and neonatal outcomes in hypertensive disorder of pregnancy: a systematic review. J Renin Angiotensin Aldosterone Syst. 2014 Mar;15(1):88-96. doi: 10.1177/1470320313475910. Epub 2013 Feb 22. Review.</citation>
    <PMID>23435582</PMID>
  </reference>
  <reference>
    <citation>Gallagher D, Adji A, O'Rourke MF. Validation of the transfer function technique for generating central from peripheral upper limb pressure waveform. Am J Hypertens. 2004 Nov;17(11 Pt 1):1059-67. Review.</citation>
    <PMID>15533735</PMID>
  </reference>
  <reference>
    <citation>Butlin M, Qasem A, Avolio AP. Estimation of central aortic pressure waveform features derived from the brachial cuff volume displacement waveform. Annu Int Conf IEEE Eng Med Biol Soc. 2012;2012:2591-4. doi: 10.1109/EMBC.2012.6346494.</citation>
    <PMID>23366455</PMID>
  </reference>
  <results_reference>
    <citation>Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation. 2004 Jun 15;109(23 Suppl 1):III27-32. Review.</citation>
    <PMID>15198963</PMID>
  </results_reference>
  <results_reference>
    <citation>Archer SL, Huang JM, Hampl V, Nelson DP, Shultz PJ, Weir EK. Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K channel by cGMP-dependent protein kinase. Proc Natl Acad Sci U S A. 1994 Aug 2;91(16):7583-7.</citation>
    <PMID>7519783</PMID>
  </results_reference>
  <results_reference>
    <citation>Podjarny E, Ben-Chetrit S, Rathaus M, Korzets Z, Green J, Katz B, Bernheim J. Pregnancy-induced hypertension in rats with adriamycin nephropathy is associated with an inadequate production of nitric oxide. Hypertension. 1997 Apr;29(4):986-91.</citation>
    <PMID>9095088</PMID>
  </results_reference>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>August 15, 2016</study_first_submitted>
  <study_first_submitted_qc>September 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2016</study_first_posted>
  <last_update_submitted>September 4, 2016</last_update_submitted>
  <last_update_submitted_qc>September 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension,</keyword>
  <keyword>Nitric Oxide</keyword>
  <keyword>L-Arginine</keyword>
  <keyword>Arterial Stiffness</keyword>
  <keyword>Ambulatory blood pressure measurement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

